Pharmaceuticals

Intravenous Iron Drugs Market Trends 2025–2029: Forecasts for Key Growth Segments

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Intravenous Iron Drugs Industry Compare Between 2025 And 2029?

The market for intravenous iron drugs has experienced substantial growth in recent years. This market is projected to expand from $3.44 billion in 2024 to $3.81 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.6%. Historically, this expansion has been driven by factors such as the increasing prevalence of iron deficiency anemia, a rising occurrence of chronic diseases, growing healthcare expenditures, an aging global population, and a higher incidence of relevant target illnesses.

The intravenous iron drugs market size is set to experience significant expansion over the next few years. It is projected to reach $5.73 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.8%. This anticipated growth during the forecast period can be primarily linked to government initiatives, ongoing research and development within the realm of IV iron drugs, an escalating demand for intravenous iron medicines, a growing number of research and development activities, and advancements in administration and formulation. Noteworthy trends anticipated in the forecast period include advanced intravenous iron therapies, progress in drug development, a move towards more convenient IV iron therapies, strategic collaborations, partnerships, and acquisitions, alongside innovations in novel drug delivery systems.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

Which Factors And Drivers Are Influencing The Intravenous Iron Drugs Market In 2025?

The rising prevalence of chronic kidney disease (CKD) is anticipated to propel the growth of the intravenous iron drugs market in the future. CKD refers to the progressive loss of kidney function over time, leading to the kidneys’ diminished capacity to effectively filter waste and excess fluids from the blood. This increasing occurrence of chronic kidney disease (CKD) results from higher rates of diabetes and hypertension, which contribute to kidney deterioration over time. Intravenous iron medications assist chronic kidney disease patients by replenishing iron stores, correcting anemia, and improving hemoglobin levels, which enhances oxygen transport and reduces the need for erythropoiesis-stimulating agents. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic kidney disease (CKD) mortality rates increased by 4.2% in 2021 and 6.2% in 2022. In 2022, CKD was responsible for approximately 22,000 deaths in Australia, constituting 11% of all fatalities. Therefore, the growing incidence of chronic kidney disease (CKD) is a key driver for the expansion of the intravenous iron drugs market.

What Are The Key Segments In The Intravenous Iron Drugs Market?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

What Trends Are Expected To Drive The Intravenous Iron Drugs Market?

Leading companies in the intravenous iron drugs market are channeling their efforts into developing innovative treatments, such as intravenous (IV) iron replacement therapy, to enhance efficacy, safety, and patient outcomes. Intravenous (IV) iron replacement therapy represents a medical procedure that directly administers iron into the bloodstream via an intravenous infusion. This therapeutic approach addresses iron deficiency and anemia, particularly benefiting patients who are unable to tolerate or adequately absorb oral iron supplements. For example, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company specializing in pioneering drug development and healthcare solutions, declared that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for the management of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III, aiming to improve exercise capacity. Injectafer is a widely employed intravenous iron therapy recognized for its rapid replenishment of iron levels in individuals who cannot tolerate or respond inadequately to oral iron supplements.

Which Industry Leaders Are Driving Innovation Across The Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy’s Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Intravenous Iron Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

Browse Through More Reports Similar to the Global Intravenous Iron Drugs Market 2025, By The Business Research Company

Iron Ore Pellets Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iron-ore-pellets-global-market-report

Iron And Steel Mills And Ferroalloy Market 2025

https://www.thebusinessresearchcompany.com/report/iron-and-steel-mills-and-ferroalloy-market

Iron And Steel Casting Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iron-and-steel-casting-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795